Associated Genetic Biomarkers
Myeloid cell leukemia 1 (MCL1) is a gene that encodes a protein that inhibits apoptotic cell death. Missense mutations, nonsense mutations, silent mutations, and in-frame deletions are observed in cancers such as bone cancer, eye cancer, and lung cancer.
MCL1 is altered in 1.09% of all cancers with breast invasive ductal carcinoma, lung adenocarcinoma, bladder urothelial carcinoma, high grade ovarian serous adenocarcinoma, and prostate adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in MCL1 are MCL1 Amplification (1.27%) and MCL1 Loss (0.00%) .
MCL1 status serves as an inclusion eligibility criteria in 2 clinical trials, of which 0 are open and 2 are closed. Of the trials that contain MCL1 status as an inclusion criterion, 2 are phase 2 (0 open).
Trials with MCL1 status in the inclusion eligibility criteria most commonly target acute myeloid leukemia .
The most frequent alterations to serve as inclusion eligibility criteria are MCL1 Amplification and MCL1 Expression .
Alvocidib, cytarabine, and mitoxantrone are the most frequent therapies in trials with MCL1 as an inclusion criteria .
Significance of MCL1 in Diseases
Malignant Solid Tumor +
Acute Myeloid Leukemia +
MCL1 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 0 are open and 1 is closed. Of the trial that contains MCL1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.